Q-omics provides the consensus-scored RTL8B profile across patient tissues and cancer cell-line models. RTL8B expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RTL8B is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, RTL8B RNA expression shows 18,172 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, KIRC, and KIRP as cancer lineages where RTL8B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RTL8B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RTL8B survival associations across molecular data types. RTL8B RNA expression shows survival associations in the most cancer types (30), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RTL8B RNA expression–survival associations across cancer types. High RTL8B expression shows unfavorable associations in BLCA, BRCA, KIRP, STAD and KICH, but favorable associations in UVM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RTL8B RNA expression.
This table summarizes RTL8B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RTL8B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RTL8B shows lower tumor expression in BLCA, THCA and UCEC and higher tumor expression in KIRC, KIRP and CHOL. The KIRC box plot shows higher RTL8B RNA expression in tumor versus normal tissue (log2 FC = +0.395, t-test p < 0.001).
This table shows molecular features associated with RTL8B in patient tissues and cancer cell lines. In patient samples, RTL8B shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, RTL8B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SKIN.
